Ruthenium complexes bearing glucosyl ligands are able to inhibit the amyloid aggregation of short histidine-peptides-Reference-Cited by-同舟云学术

Ruthenium complexes bearing glucosyl ligands are able to inhibit the amyloid aggregation of short histidine-peptides

Published:2023 Issue:25 Volume:52 Page:8549-8557
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Florio Daniele¹,La Manna Sara¹,Annunziata Alfonso²,Iacobucci Ilaria²³^ORCID,Monaco Vittoria²³,Di Natale Concetta⁴,Mollo Valentina⁵,Ruffo Francesco²,Monti Maria²³,Marasco Daniela¹^ORCID

Affiliation:

1. Department of Pharmacy, University of Naples Federico II, 80131, Naples, Italy

2. Department of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy

3. CEINGE Biotecnologie Avanzate “Franco Salvatore” S.c.a r.l., 80131, Naples, Italy

4. Interdisciplinary Research Centre on Biomaterials (CRIB), Department of Ingegneria Chimica del Materiali e della Produzione Industriale (DICMAPI), University Federico II, 80125 Naples, Italy

5. Center for Advanced Biomaterials for Healthcare, Istituto Italiano di Tecnologia (IIT), Largo Barsanti e Matteucci 53, Naples 80125, Italy

Abstract

A series of Ru-complexes sharing three-legged piano-stool structures based on the arene ring and glucosylated carbene ligands was investigated as an inhibitor of amyloid His-peptides.

Funder

Associazione Italiana per la Ricerca sul Cancro

Ministero dell'Università e della Ricerca

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/DT/D3DT01110K

Reference64 articles.

1. Metallodrugs as Anticancer Chemotherapeutics and Diagnostic Agents: A Critical Patent Review (2010-2020)

2. Metallodrugs are unique: opportunities and challenges of discovery and development